Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Venous Thromboembolism 15 Venous Thrombosis 11 Pulmonary Embolism 10 Neoplasms 9 Thrombosis 4 Thromboembolism 4 Pancreatic Neoplasms 4 Lung Neoplasms 4 Multiple Myeloma 3 Neoplasm Metastasis 2 Lymphoma 2 Hemorrhage 2 Colorectal Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Uterine Cervical Neoplasms 1 Thrombophilia 1 Thrombocytopenia 1 Thrombocythemia, Essential 1 Stomach Neoplasms 1 Small Cell Lung Carcinoma 1 Sarcoma 1 Rectal Neoplasms 1 Prostatic Neoplasms 1 Primary Myelofibrosis 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Precancerous Conditions 1 Ovarian Neoplasms 1 Obesity 1 Neoplasms, Plasma Cell 1

Interventions

Paclitaxel 326 Carboplatin 318 Bevacizumab 167 Gemcitabine 106 pembrolizumab 101 liposomal doxorubicin 100 Cyclophosphamide 96 Topotecan 93 Cisplatin 89 olaparib 86 niraparib 60 Docetaxel 56 Taxes 52 Doxorubicin 50 Drug Therapy 42 fludarabine 40 Filgrastim 39 Nivolumab 37 Etoposide 32 Specimen Handling 31 Magnetic Resonance Spectroscopy 29 Immunoglobulin G 27 Disulfides 27 Peripheral Blood Stem Cell Transplantation 26 Albumin-Bound Paclitaxel 25 durvalumab 24 aldesleukin 24 Hyperthermic Intraperitoneal Chemotherapy 24 Oxaliplatin 23 Biopsy 21

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Ovarian Neoplasms × Dalteparin × Clear all

NCT00239980 2010-02-03

FOCUS

Ontario Clinical Oncology Group (OCOG)

Phase 2 Completed

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡